S

Sanofi

Global pharma company; vaccines and R&D

Thought Leader Liaison - Oncology

Full-TimeUpdated on 10/23/2026Deadline 10/27/26
$146.3k - $243.8k
Mid
Bachelor's, Master's
Remote in USA
RemoteMust reside within the assigned territory or a reasonable distance as determined by leadership.
Growth & MarketingMarketing Generalist & Management, Product Marketing

About the job

Requirements
  • A bachelor's degree is required.
  • At least four years of work experience in field sales, product marketing, or medical or clinical experience in the same or a related therapeutic area within the pharmaceutical or biotechnology industry is required.
  • Strong organizational skills are required.
  • Ability to travel to meetings, trainings, and programs as necessary is required.
  • A valid driver's license is required.
  • Must reside within the assigned territory or within a reasonable distance as determined by leadership.
  • Travel is likely to be 60%–75%, potentially less depending on geography.
Responsibilities
  • Align with cross-functional teammates to orchestrate resources with top key opinion leaders as determined by the brand team, using influence and centers-of-excellence mapping.
  • Identify, profile, cultivate, and maintain long-term relationships with key opinion leaders in the oncology community.
  • Engage in on-label conversations about products, disease states, and the company at appropriate venues.
  • Execute unique, on-label, approved key opinion leader programming, including disease-state and product programming, as directed by leadership.
  • Partner with national, state, and local nursing organizations to support education on specific disease states.
  • Collaborate and communicate compliantly with the field team on assigned key opinion leaders to ensure strategic and tactical cohesiveness.
  • Serve as the single point of contact for resolving key opinion leader issues.
  • Use a customer-centric, needs-based approach with targeted key opinion leaders.
  • Plan and execute key opinion leader engagements and executive encounters at local, regional, and national conferences, points of action meetings, field visits, and other venues in a compliant manner.
  • Capture feedback based on brand needs through live interactions with targeted customers and key opinion leaders.
  • Obtain feedback from targeted key opinion leaders on new and existing brand-related marketing strategies and materials; materials and programs must be approved by legal, compliance, and regulatory functions.
  • Participate as a member of cross-functional brand teams to provide feedback on strategy, messaging, tactical execution, and novel programming ideas and concepts.
  • Provide competitive intelligence gained through interactions to help shape strategy.
  • Facilitate cross-functional planning, recruitment, and execution of regional and national advisory boards, capturing feedback to inform brand decisions.
  • Identify, align, and recruit appropriate health care professional consultants to meet needs profiled by marketing leaders and organizational goals for each project.
  • Assist with key opinion leader development, including identifying and training or coaching promotional speakers using approved slide decks and materials for physicians, pharmacists, and nurses.
  • Assist with speaker contracting when requested, including annual budget planning, recommendations and nominations, tiering, debarment, fair market value, and contract execution.
  • Train speakers compliantly on approved promotional slide decks and assist with completion of annual compliance training.
  • Plan and execute the annual speaker training summit and ensure speakers are updated on content changes before program execution.
  • Attend all live health care professional Thought Leader Liaison regional programming to observe, coach, and remediate speakers as necessary to ensure compliant execution of content.
  • Assist with creating new content, updating existing content, and completing annual renewals.
  • Manage monthly reporting on speaker program key performance indicators and field force performance.
  • Serve as the single point of contact for high-volume speaker logistics and scheduling, working cross-functionally to ensure appropriate communication.
  • Lead planning, execution, and pull-through of group purchasing organization in-practice programs.
Desired Qualifications
  • A master's degree in a related field is preferred.
  • Oncology experience is preferred.
  • Demonstrated leadership skills are preferred.
  • Multiple myeloma experience is preferred.
  • Launch experience is preferred.
  • Marketing experience is preferred.
  • Ability to assemble and lead cross-functional teams toward a shared vision of success is preferred.
  • Ability to present ideas effectively to individuals or groups and tailor presentations to audience needs is preferred.
  • Infusion product experience is a plus.
  • Strong project management experience, including analytical and planning skills, is preferred.
  • Ability to manage multiple projects simultaneously is preferred.
  • Ability to execute strategic and tactical plans under tight timelines is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...